WallStreetZenWallStreetZen

NASDAQ: RGEN
Repligen Corp Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Repligen earnings were $1.7M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest RGEN earnings report on Sep 30, 2025 announced Q3 2025 earnings of $14.9M, up 0.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RGEN reported annual earnings of -$25.5M, with -171.7% growth. The next RGEN earnings date is Feb 25, 2026.

RGEN past earnings growth

How has RGEN's earnings growth performed historically?

Company
N/A
Industry
9.64%
Market
55.58%
RGEN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RGEN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

RGEN earnings history

Current Revenue
$707.9M
Current Earnings
$1.7M
Current Profit Margin
0.2%
RGEN's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

RGEN Return on Equity

Current Company
0.1%
Current Industry
9.6%
Current Market
35.1%
RGEN's Return on Equity (0.1%)... subscribe to Premium to read more.
High Return on Equity Performance

RGEN Return on Assets

Current Company
0.1%
Current Industry
8.3%
RGEN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RGEN announces earnings.

RGEN Return on Capital Employed

Current Company
0.94%
Current Industry
11.1%
RGEN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RGEN vs Medical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RGEN$121.01M$1.74M-52.53%$0.02
ATR$841.57M$419.39M+14.26%$6.35
BLCO$500.00M-$305.00MN/A-$0.87
BAX$998.00M-$341.00MN/A-$0.66
MMSI$313.03M$118.43M+26.70%$2.01
View Top Medical Stocks

RGEN earnings dates

Next earnings date
Feb 25, 2026

Repligen Earnings Reports & History FAQ

What were Repligen's earnings last quarter?

On RGEN's earnings call on Invalid Date, Repligen (NASDAQ: RGEN) reported Q3 2025 earnings per share (EPS) of $0.27, up 2,800% year over year. Total RGEN earnings for the quarter were $14.91 million. In the same quarter last year, Repligen's earnings per share (EPS) was -$0.01.

If you're new to stock investing, here's how to buy Repligen stock.

When does Repligen report earnings?

The next RGEN earnings call is Invalid Date. Add RGEN to your watchlist to be reminded of Repligen's next earnings date.

Is Repligen profitable or losing money?

As of the last Repligen earnings report, Repligen is currently profitable. Repligen's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $1.74 million, a 121.47% decrease year over year.

What was RGEN's earnings growth in the past year?

As of Repligen's earnings date in Invalid Date, Repligen's earnings has grown year over year. RGEN earnings in the past year totalled $1.74 million.

What are Repligen's earnings expectations?

The current EPS estimate for Repligen's earnings report in Invalid Date is $0.44.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.